Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders




Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, Quebec–(BUSINESS WIRE)–Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2022 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec. The detailed results of the votes received by proxy are as follows:

Election of Directors

 

Director Nominees

 

NUMBER OF SHARES 

 

PERCENTAGE OF VOTES CAST

 

FOR

 

WITHHELD

 

FOR

 

WITHHELD

Daniel N. Chicoine

 

4,616,653

 

148,815

 

96.9%

 

3.1%

David A. Copeland

 

4,378,536

 

386,932

 

91.9%

 

8.1%

Anthony E. Dobranowski

 

4,363,268

 

402,200

 

91.6%

 

8.4%

John C. London

 

4,375,612

 

389,856

 

91.8%

 

8.2%

Thomas Schlader

 

4,692,345

 

73,123

 

98.5%

 

1.5%

Deborah Shannon-Trudeau

 

4,705,132

 

60,336

 

98.7%

 

1.3%

Appointment of External Auditors

 

Outcome

 

NUMBER OF SHARES

 

PERCENTAGE OF VOTES CAST

 

FOR

 

WITHHELD

 

FOR

 

WITHHELD

Ernst & Young LLP reappointed

 

5,442,357

 

15,130

 

99.7%

 

0.3%

Approval of the Continuation of Crescita’s Shareholder Rights Plan

 

Outcome

 

NUMBER OF SHARES

 

PERCENTAGE OF VOTES CAST

 

FOR

 

AGAINST

 

FOR

 

AGAINST

Shareholder Rights Plan approved

 

4,648,487

 

116,981

 

97.5%

 

2.5%

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.

Contacts

Crescita Therapeutics
Investor Relations

Linda Kisa, CPA, CA

Email: lkisa@crescitatx.com
Source: Crescita Therapeutics